Ostarine (MK2866)
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 202103

CAS#: 841205-47-8

Description: Ostarine, aslo known as Enobosarm, and MK-2866 and GTX-024, is selective androgen receptor modulator with anabolic activity. Selective androgen receptor modulator (SARM) GTx-024 is designed to work like testosterone, thus promoting and/or maintaining libido, fertility, prostate growth, and muscle growth and strength. Mimicking testosterone's action, this agent may increase lean body mass, thereby ameliorating muscle wasting in the hypermetabolic state of cancer cachexia.


Price and Availability

Size
Price

2g
USD 150
20g
USD 750
200g
USD 3250
Size
Price

5g
USD 250
50g
USD 1450
500g
USD 4250
Size
Price

10g
USD 450
100g
USD 2450
1kg
USD 6850

Ostarine (MK2866), purity > 98%, is in stock. The same day shipping out after order is received. Note: the estimated shipping out time for order > 100g may be 2 weeks.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 202103
Name: Ostarine (MK2866)
CAS#: 841205-47-8
Chemical Formula: C19H14F3N3O3
Exact Mass: 389.09873
Molecular Weight: 389.33
Elemental Analysis: C, 58.61; H, 3.62; F, 14.64; N, 10.79; O, 12.33


Synonym: MK2866; MK 2866; MK-2866; GTX024; GTX 024; GTX-024; Ostarine; Enobosarm.

IUPAC/Chemical Name: ((2S)-3-(4-cyanophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide)

InChi Key: JNGVJMBLXIUVRD-SFHVURJKSA-N

InChi Code: InChI=1S/C19H14F3N3O3/c1-18(27,11-28-15-6-2-12(9-23)3-7-15)17(26)25-14-5-4-13(10-24)16(8-14)19(20,21)22/h2-8,27H,11H2,1H3,(H,25,26)/t18-/m0/s1

SMILES Code: O=C(NC1=CC=C(C#N)C(C(F)(F)F)=C1)[C@@](C)(O)COC2=CC=C(C#N)C=C2


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:

Safety Data Sheet (MSDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information

Ostarine (also known as GTx-024 and MK-2866) is an investigational selective androgen receptor modulator (SARM) from GTX, Inc for treatment of conditions such as muscle wasting and osteoporosis, formerly under development by Merck & Company.  GTx and Merck had clinical development plans to evaluate Ostarine for the treatment of muscle loss in patients with COPD and for the treatment of chronic sarcopenia. They had a goal of initiating an Ostarine Phase II COPD clinical trial in the first quarter of 2010 and an Ostarine Phase IIb chronic sarcopenia clinical trial in 2010. (source: http://en.wikipedia.org/wiki/Ostarine ).
 
 


References

1: Girgis CM, Mokbel N, Digirolamo DJ. Therapies for musculoskeletal disease: can we treat two birds with one stone? Curr Osteoporos Rep. 2014 Jun;12(2):142-53. doi: 10.1007/s11914-014-0204-5. Review. PubMed PMID: 24633910; PubMed Central PMCID: PMC4083371.

2: Srinath R, Dobs A. Enobosarm (GTx-024, S-22): a potential treatment for cachexia. Future Oncol. 2014 Feb;10(2):187-94. doi: 10.2217/fon.13.273. PubMed PMID: 24490605.

3: Dalton JT, Taylor RP, Mohler ML, Steiner MS. Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer. Curr Opin Support Palliat Care. 2013 Dec;7(4):345-51. doi: 10.1097/SPC.0000000000000015. Review. PubMed PMID: 24189892.

4: Kim J, Wang R, Veverka KA, Dalton JT. Absorption, distribution, metabolism and excretion of the novel SARM GTx-024 [(S)-N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylp ropanamide] in rats. Xenobiotica. 2013 Nov;43(11):993-1009. doi: 10.3109/00498254.2013.788233. Epub 2013 Apr 22. PubMed PMID: 24074268.

5: de Rijke E, Essers ML, Rijk JC, Thevis M, Bovee TF, van Ginkel LA, Sterk SS. Selective androgen receptor modulators: in vitro and in vivo metabolism and analysis. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2013;30(9):1517-26. doi: 10.1080/19440049.2013.810346. Epub 2013 Jul 24. PubMed PMID: 23883284.

6: Mohd Fauzi F, Koutsoukas A, Cunningham A, Gallegos A, Sedefov R, Bender A. Computer-aided (in silico) approaches in the mode-of-action analysis and safety assessment of ostarine and 4-methylamphetamine. Hum Psychopharmacol. 2013 Jul;28(4):365-78. doi: 10.1002/hup.2322. PubMed PMID: 23881885.

7: Fearon KH. Selective androgen receptor modulators in cancer cachexia? Lancet Oncol. 2013 Apr;14(4):271-2. doi: 10.1016/S1470-2045(13)70068-8. Epub 2013 Mar 14. PubMed PMID: 23499391.

8: Dobs AS, Boccia RV, Croot CC, Gabrail NY, Dalton JT, Hancock ML, Johnston MA, Steiner MS. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol. 2013 Apr;14(4):335-45. doi: 10.1016/S1470-2045(13)70055-X. Epub 2013 Mar 14. PubMed PMID: 23499390.

9: Gerber DE. Miscellaneous agents--cytotoxics and hormonal agents. J Thorac Oncol. 2012 Dec;7(16 Suppl 5):S387-9. doi: 10.1097/JTO.0b013e31826df198. Review. PubMed PMID: 23160328.

10: Dalton JT, Barnette KG, Bohl CE, Hancock ML, Rodriguez D, Dodson ST, Morton RA, Steiner MS. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle. 2011 Sep;2(3):153-161. Epub 2011 Aug 2. PubMed PMID: 22031847; PubMed Central PMCID: PMC3177038.